NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Ltd. Kck sold 5,270,845 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
NeuroPace Trading Up 0.1 %
NeuroPace stock traded up $0.02 during trading on Thursday, reaching $13.47. 55,386 shares of the company were exchanged, compared to its average volume of 220,546. The stock’s 50 day simple moving average is $12.37 and its two-hundred day simple moving average is $9.34. The company has a market capitalization of $402.08 million, a P/E ratio of -13.41 and a beta of 2.05. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace, Inc. has a 52-week low of $5.45 and a 52-week high of $17.47.
Institutional Investors Weigh In On NeuroPace
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KCK LTD. purchased a new position in shares of NeuroPace during the 4th quarter worth $58,981,000. Jane Street Group LLC acquired a new position in NeuroPace in the fourth quarter valued at about $1,120,000. Jacobs Levy Equity Management Inc. purchased a new position in NeuroPace during the fourth quarter worth about $639,000. JPMorgan Chase & Co. increased its position in shares of NeuroPace by 440.4% during the fourth quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company’s stock valued at $725,000 after acquiring an additional 52,829 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of NeuroPace in the 4th quarter valued at approximately $369,000. Institutional investors and hedge funds own 78.83% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Report on NeuroPace
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Read More
- Five stocks we like better than NeuroPace
- The How and Why of Investing in Gold Stocks
- Tesla: 2 Reasons to Buy, 1 Reason to Run
- What Are Dividend Contenders? Investing in Dividend Contenders
- Should You Hold NVIDIA Stock for the Long Haul or Trade It?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.